ElectroCore strengthens its patent portfolio by issuing

ROCKAWAY, NJ, Sep 21, 2022 (GLOBE NEWSWIRE) — ElectroCore, Inc. (Nasdaq: ECOR), a industrial digital biopharmaceutical firm, at the moment introduced that the US Patent and Trademark Workplace (USPTO) has issued 4 patents associated to non-invasive vagus nerve stimulation (nVNS) and different applied sciences, together with the next patents: :

  • US Patent No. 11,406,825 “Cellular Cellphone for Therapy of a Affected person with Dementia” issued August 9, 2022. This patent is usually related to nVNS therapies for the therapy of neurodegenerative illnesses, comparable to dementia or Alzheimer’s illness utilizing a stimulator coupled to a cellular machine, comparable to a cell phone;
  • US Patent No. 11,432,760 “Units and Strategies for Distant Remedy and Affected person Monitoring” issued on September 6, 2022. This patent is usually related to nVNS which features a catalyst coupled to a cellular machine, comparable to a cell phone the place the catalyst is used able to transmitting knowledge to the cellular machine which incorporates, amongst others, the place of the electrode(s) on the floor of the pores and skin relative to the goal nerve;
  • US Patent No. 11.439,818 titled “Electrical Nerve Stimulation for Therapy of Gastroparesis, Useful Dyspepsia, and Different Useful Gastrointestinal Issues” issued September 13, 2022. This patent is usually related to nVNS therapies for the therapy of postoperative ileus; And the
  • US Patent No. 11446491 titled “A Stimulator for Use with a Transportable Machine” issued on September 20, 2022. This patent is one other in a sequence of patents acquired by ElectroCore that usually relate to using nerve stimulators with moveable gadgets, comparable to a cell phone. The patent consists of claims for the machine and methodology for producing {an electrical} impulse with a stimulator coupled with a conveyable machine and making use of electrical impulses throughout the outer pores and skin floor to a goal website within the affected person.

“We’re delighted to obtain these 4 new patents from the USPTO, additional strengthening our mental patent portfolio,” stated Dan Goldberger, CEO of ElectroCore. “These new patents help our cellular connectivity platform, via using cellular gadgets paired with a stimulator to ship nVNS remedy. The addition of those patents underscores our dedication to advancing remedy past those that undergo from migraine and cluster complications, and we sit up for persevering with to discover the position of nVNS. in several instances.

About ElectroCore, Inc.
ElectroCore, Inc. is a industrial bioelectronic firm devoted to bettering affected person outcomes via a non-invasive therapy platform for vagus nerve stimulation, initially targeted on treating a number of circumstances in neuroscience. The corporate’s present indications are preventive therapy of cluster headache and migraine, acute therapy of migraine and episodic cluster headache, acute and prophylactic therapy of migraine in adolescents, and paroxysmal and chronic migraine and migraine in adults.

For extra data, go to www.electrocore.com.

About gammaCore™
gammaCore™ (nVNS) is the primary non-invasive, guide medical therapy utilized to the neck for the therapy of migraines and cluster complications via using delicate electrical stimulation of the vagus nerve that passes via the pores and skin. Designed as a conveyable, easy-to-use know-how, gammaCore is self-administered by sufferers, as wanted, with out the potential uncomfortable side effects related to generally prescribed medicines. When positioned on a affected person’s neck above the vagus nerve, Gamma Core stimulates afferent fibers within the nerve, which can cut back ache in sufferers.

gammaCore (nVNS) is licensed by the FDA in the US to be used as an adjunct within the prophylaxis of cluster headache in grownup sufferers, the acute therapy of ache related to episodic cluster headache in grownup sufferers, and the acute prophylactic therapy of migraine in adolescents (aged between 12 and older) and grownup sufferers, and paroxysmal hemiplegia persists in grownup sufferers. Jamacor is CE marked within the European Union for the acute and/or prophylactic therapy of major complications (migraine, cluster headache and trigeminal headache).

Autonomic complications and Hemicrania Continua) and overuse headache medicines in adults.

Jamacor is contraindicated in sufferers if:

  • Have an energetic implantable medical machine, comparable to a pacemaker, listening to support implant, or different implantable digital machine
  • Have a steel machine, comparable to a brace, bone plate, or bone screw, implanted in or close to your neck
  • You might be utilizing one other machine on the similar time (for instance, a transcutaneous electrical nerve stimulation unit, a muscle stimulator) or any moveable digital machine (comparable to a cell phone)

The protection and efficacy of Gamacor haven’t been evaluated within the following sufferers:

  • Adolescent sufferers with congenital coronary heart issues
  • Sufferers recognized with narrowing of the arteries (carotid atherosclerosis)
  • Sufferers who’ve had surgical procedure to chop the vagus nerve within the neck (cervicotomy)
  • Pediatric sufferers (below 12 years of age)
  • pregnant girls
  • Sufferers with hypertension, hypotension, bradycardia or tachycardia

For extra data, please go to gammaCore.com.

forward-looking statements
This press launch could include forward-looking statements throughout the which means of the Personal Securities Litigation Reform Act of 1995. Such forward-looking statements embody, however are usually not restricted to, statements concerning ElectroCore’s enterprise prospects, medical plans and product growth; its pipeline or potential markets for its applied sciences; timing, consequence and impression of regulatory, medical and industrial developments; Issuance of US and worldwide patents that present prolonged mental property protection; the potential for future enterprise fashions and income streams from the corporate’s potential mixture of nVNS and smartphone or application-based applied sciences; The supply and impression of motivation protection, the potential of nVNS generally and gammaCore specifically and different phrases that aren’t historic in nature, notably those who use phrases comparable to “expects,” “expects,” “believes,” “intends,” phrases with related which means, and derivatives of those phrases and using future dates Precise outcomes could differ from these projected in any forward-looking statements attributable to many components These components embody, amongst different issues, the power to acquire further financing essential to proceed ElectroCore’s enterprise, gross sales, advertising and marketing and product growth plans, and inherent uncertainties within the growth of latest merchandise or applied sciences, the power to efficiently market gammaCore™, competitors within the trade wherein ElectroCore operates and normal market circumstances.All forward-looking statements are made as of the date of this press launch, and ElectroCore undertakes no obligation to replace forward-looking statements or to replace the the reason why outcomes could differ. precise than these projected within the forward-looking statements, besides as required by legislation.Buyers ought to consult with all data offered on this doc and may point out ElectroCore additionally requires disclosure of threat components set forth in ElectroCore experiences and different filings with the Securities and Change Fee, obtainable at www.sec.gov.

Buyers:
Wealthy Cockerell
CG Capital
404-736-3838
ecor@cg.capital